Intravesical interleukin-15 gene therapy in an orthotopic bladder cancer model

Human Gene Therapy

Volumn 22, Issue 11, 2011, Pages 1423-1432

  Matsumoto, Kazuhiro ^a   Kikuchi, Eiji ^a   Horinaga, Minoru ^b   Takeda, Toshikazu ^a   Miyajima, Akira ^a   Nakagawa, Ken ^a   Oya, Mototsugu ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; INTERLEUKIN 15; LIPOSOME; PLASMID VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER INHIBITION; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENETIC TRANSFECTION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; LIPOSOMAL GENE DELIVERY SYSTEM; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; NONVIRAL GENE THERAPY; THERAPY EFFECT; URETHRA;

ANIMALS; FEMALE; GENE THERAPY; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-15; MICE; MICE, INBRED C3H; TRANSFECTION; TUMOR CELLS, CULTURED; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

MUS;

EID: 81855195954     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2011.013     Document Type: Article

References (46)

1. Alexandroff, A.B., Jackson, A.M., O'Donnell, M.A., and James,-K. (1999). BCG immunotherapy of bladder cancer: 20 years on. Lancet 353, 1689-1694. (Pubitemid 29224536)
2. Anderson, W.F. (1998). Human gene therapy. Nature 392, 25-30. (Pubitemid 28215190)
3. Armitage, R.J., Macduff, B.M., Eisenman, J., et al. (1995). IL-15-has stimulatory activity for the induction of B cell proliferation-and differentiation. J. Immunol. 154, 483-490.
4. Bamford, R.N., Grant, A.J., Burton, J.D., et al. (1994). The interleukin-(IL) 2 receptor beta chain is shared by IL-2 and a cytokine,-provisionally designated IL-T, that stimulates T-cell-proliferation and the induction of lymphokine-activated killer-cells. Proc. Natl. Acad. Sci. USA 91, 4940-4944.
5. Becker, T.C., Wherry, E.J., Boone, D., et al. (2002). Interleukin 15-is required for proliferative renewal of virus specific memory-CD8 T cells. J. Exp. Med. 195, 1541-1548. (Pubitemid 34666068)
6. Böhle, A., and Brandau, S. (2003). Immune mechanisms in bacillus-Calmette-Guérin immunotherapy for superficial bladder-cancer. J. Urol. 170, 964-969. (Pubitemid 36999613)
7. Brandau, S., and Suttmann, H. (2007). Thirty years of BCG-immunotherapy for non-muscle invasive bladder cancer: a-success story with room for improvement. Biomed. Pharmacother. 61, 299-305. (Pubitemid 47189735)
8. Carson, W.E., Giri, J.G., Lindemann, M.J., et al. (1995). Interleukin-(IL) 15 is a novel cytokine that activates human natural-killer cells via components of the IL-2 receptor. J. Exp. Med. 180, 1395-1403. (Pubitemid 24289613)
9. Chapman, P.B., and Houghton, A.N. (1993). Non-antibody immunotherapy-of cancer. Curr. Opin. Immunol. 5, 726-731.
10. Colucci, F., Caligiuri, M.A., and Di Santo, J.P. (2003). What-does it take to make a natural killer? Nat. Rev. Immunol. 3,-413-425. (Pubitemid 37323201)
11. Connor, J., Bannerji, R., Saito, S., et al. (1993). Regression of-bladder tumors in mice treated with interleukin-2 gene modified-tumor cells. J. Exp. Med. 177, 1127-1134. (Pubitemid 23097401)
12. Evans, R., Fuller, J.A., Christianson, G., et al. (1997). IL-15 mediates-anti-tumor effects after cyclophosphamide injection of-tumor-bearing mice and enhances adoptive immunotherapy:-the potential role of NK cell subpopulations. Cell. Immunol. 179, 66-73. (Pubitemid 27360105)
13. Fehniger, T.A., Suzuki, K., Ponnappan, A., et al. (2001). Fatal-leukemia in interleukin 15 transgenic mice follows early expansions-in natural killer and memory phenotype CD8F T-cells. J. Exp. Med. 193, 219-231. (Pubitemid 32524453)
14. Fidler, I.J. (1990). Critical factors in the biology of human cancer-metastasis: twenty-eighth G.H.A. Clowes memorial award-lecture. Cancer Res. 50, 6130-6138. (Pubitemid 20323663)
15. Gamero, A.M., Ussery, D., Reintgen, D.S., et al. (1995). Interleukin-15 induction of lymphokine-activated killer cell function-against autologous tumor cells in melanoma patient-lymphocytes by a CD18-dependent, perforin-related mechanism. Cancer Res. 55, 4988-4994.
16. Giri, J.G., Ahdieh, M., Eisenman, J., et al. (1994). Utilization of the-beta and gamma chains of the IL-2 receptor by the novel cytokine-IL-15. EMBO J. 13, 2822-2830. (Pubitemid 24191692)
17. Grabstein, K.H., Eisenman, J., Shanebeck, K., et al. (1994). Cloning of a T cell growth factor that interacts with the beta-chain of the interleukin-2 receptor. Science 264, 965-968. (Pubitemid 24196167)
18. Hazama, S., Noma, T., Wang, F., et al. (1999). Tumour cells-engineered to secrete interleukin-15 augment anti-tumour-immune responses in vivo. Br. J. Cancer 80, 1420-1426. (Pubitemid 29308612)
19. Horiguchi, Y., Larchian, W.A., Kaplinsky, R., et al. (2000). Intravesical liposome-mediated interleukin-2 gene therapy-in orthotopic murine bladder cancer model. Gene Ther. 7,-844-851. (Pubitemid 30303581)
20. Horiguchi, Y., Kikuchi, E., Ozu, C., et al. (2008). Establishment of-orthotopic mouse superficial bladder tumor model for studies-on intravesical treatments. Human Cell 21, 57-63.
21. Horinaga, M., Harsch, K.M., Fukuyama, R., et al. (2005). Intravesical-interleukin-12 gene therapy in an orthotopic bladder-cancer model. Urology 66, 461-466. (Pubitemid 41138125)
22. Jaffee, E.M., Dranoff, G., Cohen, L.K., et al. (1993). High efficiency-gene transfer into primary human tumor explants-without cell selection. Cancer Res. 53, 2221-2226. (Pubitemid 23156803)
23. Kennedy, M.K., Glaccum, M., Brown, S.N., et al. (2000). Reversible-defects in natural killer and memory CD8 T cell lineages-in interleukin-15 deficient mice. J. Exp. Med. 191, 771-780.
24. Kikuchi, E., Menendez, S., Ozu, C., et al. (2007). Highly efficient-gene delivery for bladder cancers by intravesically administered-replication- competent retroviral vectors. Clin. Cancer-Res. 13, 4511-4518. (Pubitemid 47219721)
25. Lee, M.J., Cho, S.S., You, J.R., et al. (2002). Intraperitoneal gene-delivery mediated by a novel cationic liposome in a peritoneal-disseminated ovarian cancer model. Gene Ther. 9, 859-866.
26. Lewko, W.M., Smith, T.L., Bowman, D.J., et al. (1995). Interleukin-15 and the growth of tumor derived activated T-cells. Cancer Biother. 10, 13-20.
27. Miller, D.G., Adam, M.A., and Miller, A.D. (1990). Gene transfer-by retrovirus vectors occurs only in cells that are actively-replicating at the time of infection. Mol. Cell. Biol. 10, 4239-4942.
28. Morales, A., Eidinger, D., and Bruce, A.W. (1976). Intracavitary-Bacillus Calmette-Guerin in the treatment of superficial bladder-tumors. J. Urol. 116, 180-183.
29. Mori, A., Suko, M., Kaminuma, O., et al. (1996). IL-15 promotes-cytokine production of human T helper cells. J. Immunol. 156,-2400-2405. (Pubitemid 26091563)
30. Munger, W., DeJoy, S.Q., Jeyaseelan, R., Sr., et al. (1995). Studies-evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: comparison with interleukin-2. Cell. Immunol. 165, 289-293.
31. Nishimura, H., Yajima, T., Naiki, Y., et al. (2000). Differential-roles of interleukin 15 mRNA isoforms generated by alternative-splicing in immune responses in vivo. J. Exp. Med. 191,-157-170.
32. Ratliff, T.L. (2000). Role of animal models in understanding intravesical-therapy with bacille Calmette-Guérin. Clin. Infect. Dis. 31(suppl 3), 106-108.
33. Ratliff, T.L., Gillen, D., and Catalona, W.J. (1987). Requirement-of a thymus dependent immune response for BCG-mediated-antitumor activity. J. Urol. 137, 155-158. (Pubitemid 17214254)
34. Ratliff, T.L., Ritchey, J.K., Yuan, J.J., et al. (1993). T-cell subsets-required for intravesical BCG immunotherapy for bladder-cancer. J. Urol. 150, 1018-1023. (Pubitemid 23241327)
35. Schluns, K.S., Williams, K., Ma, A., et al. (2002). Cutting edge:-requirement for IL-15 in the generation of primary and-memory antigen-specific CD8 T cells. J. Immunol. 168, 4827-4831. (Pubitemid 34495942)
36. Siemens, D.R., Crist, S., Austin, J.C., et al. (2003). Comparison of-viral vectors: gene transfer efficiency and tissue specificity in a-bladder cancer model. J. Urol. 170, 979-984. (Pubitemid 36999616)
37. Suzuki, K., Nakazato, H., Matsui, H., et al. (2001). NK cellmediated-anti-tumor immune response to human prostate-cancer cell, PC-3, immunogene therapy using a highly secretable-form of interleukin-15 gene transfer. J. Leukoc. Biol. 69,-531-537. (Pubitemid 32294837)
38. Sylvester, R.J. (2011). Bacillus Calmette-Guérin treatment of nonmuscle-invasive bladder cancer. Int. J. Urol. 18, 113-120.
39. Takeuchi, E., Yanagawa, H., Yano, S., et al. (1996). Induction by-interleukin-15 of human killer cell activity against lung cancer-cell lines and its regulatory mechanisms. Jpn. J. Cancer Res. 87,-1251-1258. (Pubitemid 27042368)
40. Tasaki, K., Yoshida, Y., Miyauchi, M., et al. (2000). Transduction-of murine colon carcinoma cells with interleukin-15 gene induces-antitumor effects in immunocompetent and immunocompromised-hosts. Cancer Gene Ther. 7, 255-261. (Pubitemid 30194560)
41. Tori, F.M., and Lum, B.L. (1984). The biology and treatment of-superficial bladder cancer. J. Clin. Oncol. 2, 505-531. (Pubitemid 14075985)
42. Waldmann, T.A. (2006). The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat. Rev. Immunol. 6, 595-601. (Pubitemid 44134092)
43. Waldmann, T.A., Dubois, S., and Tagaya, Y. (2001). Contrasting-roles of IL-2 and IL-15 in the life and death of lymphocytes:-implications for immunotherapy. Immunity 14, 105-110. (Pubitemid 32206513)
44. Wood, M., Perrotte, P., Onishi, E., et al. (1999). Biodistribution of-an adenoviral vector carrying the luciferase reporter gene-following intravesical or intravenous administration to a-mouse. Cancer Gene Ther. 6, 367-372. (Pubitemid 129667809)
45. Yajima, T., Nishimura, H., Ishimitsu, R., et al. (2002). Overexpression-of IL-15 in vivo increases antigen-driven memory-CD8F T cells following a microbe exposure. J. Immunol. 168,-1198-1203. (Pubitemid 34094485)
46. Zhang, X., Sun, S., Hwang, I., et al. (1998). Potent and selective-stimulation of memory-phenotype CD8F T cells in vivo by IL-15. Immunity 8, 591-599. (Pubitemid 28264750)